Evidence map›Paper›PMID 38291369›Full record

ArticleBMC psychiatry2024

Demographic and clinical characteristics associated with anxiety and depressive symptom outcomes in users of a digital mental health intervention incorporating a relational agent.

Emil Chiauzzi, Andre Williams, Timothy Y Mariano, Sarah Pajarito, Athena Robinson, Andrew Kirvin-Quamme, Valerie Forman-Hoffman

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05672745 (An Open-label Pilot Study to Learn How the Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05672745 nacompletednot on this map

An Open-label Pilot Study to Learn How the Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes

TypeinterventionalSponsorWoebot HealthRan2022 to 2022Enrolled256ConditionsTo Understand the Characteristics of Digital Mental Health Intervention Users as They Relate to Mental Health OutcomesArmsWB-LIFE
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Emil ChiauzziWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Andre WilliamsWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Timothy Y MarianoWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Sarah PajaritoWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Athena RobinsonWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Andrew Kirvin-QuammeWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Valerie Forman-HoffmanWoebot Health, 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA. valerie_hoffman@woebothealth.com.
Brown University · USWilhelm Löhe University for Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigital mental health interventions (DMHIs) may reduce treatment access issues for those experiencing depressive and/or anxiety symptoms. DMHIs that incorporate relational agents may offer unique ways to engage and respond to users and to potentially help reduce provider burden. This study tested Woebot for Mood & Anxiety (W-MA-02), a DMHI that employs Woebot, a relational agent that incorporates elements of several evidence-based psychotherapies, among those with baseline clinical levels of depressive or anxiety symptoms. Changes in self-reported depressive and anxiety symptoms over 8 weeks were measured, along with the association between each of these outcomes and demographic and clinical characteristics.

methodsThis exploratory, single-arm, 8-week study of 256 adults yielded non-mutually exclusive subsamples with either clinical levels of depressive or anxiety symptoms at baseline. Week 8 Patient Health Questionnaire-8 (PHQ-8) changes were measured in the depressive subsample (PHQ-8 ≥ 10). Week 8 Generalized Anxiety Disorder-7 (GAD-7) changes were measured in the anxiety subsample (GAD-7 ≥ 10). Demographic and clinical characteristics were examined in association with symptom changes via bivariate and multiple regression models adjusted for W-MA-02 utilization. Characteristics included age, sex at birth, race/ethnicity, marital status, education, sexual orientation, employment status, health insurance, baseline levels of depressive and anxiety symptoms, and concurrent psychotherapeutic or psychotropic medication treatments during the study.

resultsBoth the depressive and anxiety subsamples were predominantly female, educated, non-Hispanic white, and averaged 38 and 37 years of age, respectively. The depressive subsample had significant reductions in depressive symptoms at Week 8 (mean change =-7.28, SD = 5.91, Cohen's d = -1.23, p < 0.01); the anxiety subsample had significant reductions in anxiety symptoms at Week 8 (mean change = -7.45, SD = 5.99, Cohen's d = -1.24, p < 0.01). No significant associations were found between sex at birth, age, employment status, educational background and Week 8 symptom changes. Significant associations between depressive and anxiety symptom outcomes and sexual orientation, marital status, concurrent mental health treatment, and baseline symptom severity were found.

conclusionsThe present study suggests early promise for W-MA-02 as an intervention for depression and/or anxiety symptoms. Although exploratory in nature, this study revealed potential user characteristics associated with outcomes that can be investigated in future studies.

trial registrationThis study was retrospectively registered on ClinicalTrials.gov (#NCT05672745) on January 5th, 2023.

Indexed as

DepressionMental HealthAdultAnxietyAnxiety DisordersEthnicityFemaleHumansInfant, NewbornMalePsychotropic DrugsPsychotropic DrugsAnxietyArtificial intelligenceChatbotConversational agentDepressionDigital mental health interventionNatural language processingRelational agentUser characteristics

Identifiers

PMID38291369
PMCPMC10826101
OpenAlexW4391359837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.